Chiroscience R&D Announces Key Milestone In PDE4 Collaboration With Schering-Plough.LONDON--(BW HealthWire)--April 29, 1999-- Chiroscience R&D is pleased to announce that it has achieved a key milestone in its PDE PDE Pennsylvania Department of Education PDE Plug-In Development Environment PDE Partial Differential Equation PDE Phosphodiesterases PDE Personal Digital Entertainment PDE Pulse Detonation Engine PDE Product Data Exchange PDE Present-Day English 4 collaboration with Schering-Plough. In June 1997, Chiroscience and Schering-Plough Research Institute signed an agreement to develop selective PDE4 inhibitors as oral treatments for asthma and other inflammatory diseases. The collaboration was designed to develop well-tolerated oral PDE4 inhibitors that can provide symptomatic relief symptomatic relief (sim·t  ·maˑ·tik r by preventing or reversing the development of airway airway /air·way/ (-wa)1. the passage by which air enters and leaves the lungs. 2. a device for securing unobstructed respiration. hyperactivity hyperactivity, excessive physical activity of emotional or physiological origin, usually seen in young children; one of the components of attention deficit hyperactivity disorder. and inflammation. Under the terms of the agreement, Schering-Plough will make a milestone payment to Chiroscience which relates to one of these PDE4 inhibitors (D4396). This compound has already completed a number of pre-clinical studies, and on successful completion of the pre-clinical phase, is projected to enter clinical trials next year. Schering-Plough has worldwide rights to products developed from this collaboration and has access to all of Chiroscience's PDE4 inhibitors in these fields. In return Chiroscience received an up-front payment in 1997 together with research and development funding. This funding is expected to continue throughout 1999 as the two companies extend their research objectives. Further payments will be made if key development milestones are reached and Chiroscience will receive royalties on any resulting product sales. Chiroscience has an extensive patent position with PDE4 inhibitors. 18 patent applications have been filed and 6 granted to date. Dr. John Padfield, Chief Executive Officer of Chiroscience commented: "Chiroscience has always believed that it had sound understanding of the role PDE4 plays in inflammatory disease and, in particular, how selective drugs can be designed to optimize the therapeutic window. Chiroscience's knowledge in this field is covered by an extensive patent estate, thus providing a strong intellectual property position. The development milestone that we have achieved marks an important step forward in our collaboration with Schering-Plough." Chiroscience Group plc Chiroscience Group plc is an emerging pharmaceutical company which uses its diverse technology platform to discover and develop novel medicines for improved healthcare. It has three businesses: Chiroscience R&D; Rapigene; and ChiroTech. Chiroscience R&D's focus is on innovative small molecule drugs and related diagnostics in the therapeutic areas of cancer, inflammation, pain, osteoporosis and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause . Its technology platform allows the conception and development of receptor-based and enzyme-inhibiting small molecule drugs with high selectivity selectivity /se·lec·tiv·i·ty/ (se-lek-tiv´i-te) in pharmacology, the degree to which a dose of a drug produces the desired effect in relation to adverse effects. selectivity 1. of action. Rapigene is involved in the creation and provision of genomic technologies and services to partner companies and to Chiroscience R&D's drug discovery programs. ChiroTech provides chiral chi·ral adj. Of or relating to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image. chi·ral technology services, catalysts and chiral products to customers within the pharmaceutical and related industries, including Chiroscience R&D. Chiroscience Group plc is listed on the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. and is based in Cambridge and Stevenage, UK and Seattle, Washington  This page is protected from moves until disputes have been resolved on the .The reason for its protection is listed on the protection policy page. , USA. Additional information on Chiroscience can be accessed on the company's home page: http://www.chiroscience.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion